1887
  1. Home
  2. Eurosurveillance
  3. Volume 21, Issue 22, 02/Jun/2016
  4. Article
Research article Open Access
Like 0
Download

Abstract

This study aims to quantify and compare preferences of citizens from different European countries for vaccination programme characteristics during pandemics, caused by pathogens which are transmitted through respiratory droplets. Internet panel members, nationally representative based on age, sex, educational level and region, of four European Union Member States (Netherlands, Poland, Spain, and Sweden, n = 2,068) completed an online discrete choice experiment. These countries, from different geographical areas of Europe, were chosen because of the availability of high-quality Internet panels and because of the cooperation between members of the project entitled Effective Communication in Outbreak Management: development of an evidence-based tool for Europe (ECOM). Data were analysed using panel latent class regression models. In the case of a severe pandemic scenario, vaccine effectiveness was the most important characteristic determining vaccination preference in all countries, followed by the body that advises on vaccination. In Sweden, the advice of family and/or friends and the advice of physicians strongly affected vaccine preferences, in contrast to Poland and Spain, where the advice of (international) health authorities was more decisive. Irrespective of pandemic scenario or vaccination programme characteristics, the predicted vaccination uptakes were lowest in Sweden, and highest in Poland. To increase vaccination uptake during future pandemics, the responsible authorities should align with other important stakeholders in the country and communicate in a coordinated manner.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.22.30247
2016-06-02
2024-12-26
/content/10.2807/1560-7917.ES.2016.21.22.30247
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/22/eurosurv-21-22-3.html?itemId=/content/10.2807/1560-7917.ES.2016.21.22.30247&mimeType=html&fmt=ahah

References

  1. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006;12(1):15-22.  https://doi.org/10.3201/eid1209.05-0979  PMID: 16494711 
  2. European Centre for Disease Prevention and Control (ECDC). The influenza A(H1N1) pandemic in Europe. Stockholm: ECDC; 2010. Available from: http://ecdc.europa.eu/en/publications/Publications/101108_SPR_pandemic_experience.pdf
  3. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12(1):9-14.  https://doi.org/10.3201/eid1201.051254  PMID: 16494710 
  4. Nicoll A, Ammon A, Amato Gauci A, Ciancio B, Zucs P, Devaux I, et al. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health. 2010;124(1):14-23.  https://doi.org/10.1016/j.puhe.2009.12.001  PMID: 20141821 
  5. European Centre for Disease Prevention and Control (ECDC), Known facts and known unknowns. Stockholm: ECDC; 2010. [Accessed 21 Oct 2015]. Available from: http://ecdc.europa.eu/en/healthtopics/Documents/0905_Pandemic_Influenza_Known_Facts_and_Known_Unknowns.pdf
  6. World Health Organization (WHO). WHO global influenza preparedness plan: the role of WHO and recommendations for national measures before and during pandemics. Geneva: WHO; 2005. Available from: http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5.pdf
  7. Fineberg HV. Pandemic preparedness and response--lessons from the H1N1 influenza of 2009. N Engl J Med. 2014;370(14):1335-42.  https://doi.org/10.1056/NEJMra1208802  PMID: 24693893 
  8. Nicoll A, Brown C, Karcher F, Penttinen P, Hegermann-Lindencrone M, Villanueva S, et al. Developing pandemic preparedness in Europe in the 21st century: experience, evolution and next steps. Bull World Health Organ. 2012;90(4):311-7.  https://doi.org/10.2471/BLT.11.097972  PMID: 22511829 
  9. World Health Organization Regional Office for Europe (WHO/Europe), European Centre for Disease Prevention and Control (ECDC). Key changes to pandemic plans by Member States of the WHO European Region based on lessons learnt from the 2009 pandemic. WHO/Europe and ECDC; 2012. Available from: http://www.euro.who.int/__data/assets/pdf_file/0006/161664/ECDC_WHO_EURO_PiP-Workshops-Summary-Report_FINAL-26032012.pdf?ua=1
  10. Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, et al. Containing pandemic influenza at the source. Science. 2005;309(5737):1083-7.  https://doi.org/10.1126/science.1115717  PMID: 16079251 
  11. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448-52.  https://doi.org/10.1038/nature04795  PMID: 16642006 
  12. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA. 2006;103(15):5935-40.  https://doi.org/10.1073/pnas.0601266103  PMID: 16585506 
  13. Lugnér AK, van Boven M, de Vries R, Postma MJ, Wallinga J. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ. 2012;345(jul12 3):e4445.  https://doi.org/10.1136/bmj.e4445  PMID: 22791791 
  14. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8(1):e1000388.  https://doi.org/10.1371/journal.pmed.1000388  PMID: 21379316 
  15. Mereckiene J, Cotter S, Weber JT, Nicoll A, D’Ancona F, Lopalco PL, et al. VENICE project gatekeepers group. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. Euro Surveill. 2012;17(4):20064. PMID: 22297139 
  16. Gesser-Edelsburg A, Mordini E, James JJ, Greco D, Green MS. Risk Communication Recommendations and Implementation During Emerging Infectious Diseases: A Case Study of the 2009 H1N1 Influenza Pandemic. Disaster Med Public Health Prep. 2014;8(02): 158-69.  https://doi.org/10.1017/dmp.2014.27  PMID: 24735822 
  17. Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. Addressing the vaccine confidence gap. Lancet. 2011;378(9790):526-35.  https://doi.org/10.1016/S0140-6736(11)60678-8  PMID: 21664679 
  18. Influenza H1N1 Analytical Report - Eurobarometer on Influenza H1N1. The Gallup Organization; 2010. Available from: http://ec.europa.eu/public_opinion/flash/fl_287_en.pdf
  19. O’Flanagan D, Cotter S, Mereckiene J. Pandemic A(H1N1) 2009 Influenza Vaccination Survey, Influenza season 2009/2010. VENICE II Consortium; 2011. Available from: http://venice.cineca.org/Final_Report_VENICE_Pandemic_Influenza_2009.pdf
  20. Ryan M. Discrete choice experiments in health care. BMJ. 2004;328(7436):360-1.  https://doi.org/10.1136/bmj.328.7436.360  PMID: 14962852 
  21. Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge: Cambridge University Press; 2005.
  22. Luce D, Tukey J. Simultaneous conjoint measurement: a new type of fundamental measurement. J Math Psychol. 1964;1(1):1-27.  https://doi.org/10.1016/0022-2496(64)90015-X 
  23. Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883-902.  https://doi.org/10.1007/s40273-014-0170-x  PMID: 25005924 
  24. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3-13.  https://doi.org/10.1016/j.jval.2012.08.2223  PMID: 23337210 
  25. Monthly comparative price levels. Organisation for Economic Co-operation and Development (OECD), 2015. [Accessed 27 Oct 2015]. Available from: http://stats.oecd.org/Index.aspx?QueryId=24057
  26. Organisation for Economic Co-operation and Development (OECD). Main economic indicators. OECD; 2013. Available from: http://dx.doi.org/10.1787/mei-v2013-5-en
  27. Determann D, Korfage IJ, Lambooij MS, Bliemer M, Richardus JH, Steyerberg EW, et al. Acceptance of vaccinations in pandemic outbreaks: a discrete choice experiment. PLoS One. 2014;9(7):e102505.  https://doi.org/10.1371/journal.pone.0102505  PMID: 25057914 
  28. International Organization for Standardization (ISO). ISO 26362:2009(en) Access panels in market, opinion and social research. ISO. [Accessed 29 Sep 2015]. Available from: www.iso.org/obp/ui/#iso:std:iso:26362:ed-1:v1:en
  29. International Organization for Standardization (ISO). ISO 20252:2012(en) Market, opinion, and social research International Organization for Standardization (ISO). ISO. [Accessed 29 Sep 2015]. Available from: www.iso.org/obp/ui/#iso:std:iso:20252:ed-2:v1:en
  30. International Organization for Standardization (ISO). ISO 14001:2015(en) Environmental management systems. ISO. [Accessed 14 Oct 2015]. International Organization for Standardization (ISO), Available from: www.iso.org/obp/ui/#iso:std:iso:14001:ed-3:v1:en
  31. The ICC/ESOMAR code on Market and Social Research. [Accessed 14 Oct 2015]. Available from: www.esomar.org/knowledge-and-standards/codes-and-guidelines.php
  32. Orme BK. Getting started with Conjoint Analysis: Strategies for Product Design and Pricing Research. Madison, WI: Research Publishers LLC; 2006.
  33. Wet medisch-wetenschappeljk onderzoek met mensen. [Medical Research Involving Human Subjects Act]. Dutch. [Accessed 29 Sep 2015]. Available from: http://wetten.overheid.nl/BWBR0009408
  34. Greene WH, Hensher DA. A latent class model for discrete choice analysis: contrasts with mixed logit. Transport Res B-Meth.2003;37(8):681-98.  https://doi.org/10.1016/S0191-2615(02)00046-2 
  35. Louviere JH, Hensher DA, Swait JD. Stated choice models: analysis and application. Cambridge: Cambridge University Press; 2000.
  36. Kesternich I, Heiss F, McFadden D, Winter J. Suit the action to the word, the word to the action: Hypothetical choices and real decisions in Medicare Part D. J Health Econ. 2013;32(6):1313-24.  https://doi.org/10.1016/j.jhealeco.2012.11.006  PMID: 23317633 
  37. Linley WG, Hughes DA. Decision-makers’ preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity. Pharmacoeconomics. 2013;31(4):345-55.  https://doi.org/10.1007/s40273-013-0030-0  PMID: 23516033 
  38. Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics. 2008;26(8):661-77.  https://doi.org/10.2165/00019053-200826080-00004  PMID: 18620460 
  39. Bish A, Yardley L, Nicoll A, Michie S. Factors associated with uptake of vaccination against pandemic influenza: a systematic review. Vaccine. 2011;29(38):6472-84.  https://doi.org/10.1016/j.vaccine.2011.06.107  PMID: 21756960 
  40. Sadique MZ, Devlin N, Edmunds WJ, Parkin D. The effect of perceived risks on the demand for vaccination: results from a discrete choice experiment. PLoS One. 2013;8(2):e54149.  https://doi.org/10.1371/journal.pone.0054149  PMID: 23408936 
  41. Bults M, Beaujean DJ, de Zwart O, Kok G, van Empelen P, van Steenbergen JE, et al. [Mexican flu: risk perception in the general public, precautionary measures and trust in information provided by the government]. Ned Tijdschr Geneeskd. 2010;154:A1686. PMID: 20482914 
  42. Zijtregtop EA, Wilschut J, Koelma N, Van Delden JJ, Stolk RP, Van Steenbergen J, et al. Which factors are important in adults’ uptake of a (pre)pandemic influenza vaccine? Vaccine. 2009;28(1):207-27.  https://doi.org/10.1016/j.vaccine.2009.09.099  PMID: 19800997 
  43. Agüero F, Adell MN, Pérez Giménez A, López Medina MJ, Garcia Continente X. Adoption of preventive measures during and after the 2009 influenza A (H1N1) virus pandemic peak in Spain. Prev Med. 2011;53(3):203-6.  https://doi.org/10.1016/j.ypmed.2011.06.018  PMID: 21781983 
  44. Brydak LB, Woźniak Kosek A, Nitsch-Osuch A. Influenza vaccines and vaccinations in Poland - past, present and future. Med Sci Monit. 2012;18(11):RA166-71.  https://doi.org/10.12659/MSM.883534  PMID: 23111751 
  45. Börjesson M, Enander A. Perceptions and sociodemographic factors influencing vaccination uptake and precautionary behaviours in response to the A/H1N1 influenza in Sweden. Scand J Public Health. 2014;42(2):215-22.  https://doi.org/10.1177/1403494813510790  PMID: 24259541 
  46. Seale H, Heywood AE, McLaws ML, Ward KF, Lowbridge CP, Van D, et al. Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine. BMC Infect Dis. 2010;10(1):99.  https://doi.org/10.1186/1471-2334-10-99  PMID: 20403201 
  47. Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis. 2014;14(3):227-38.  https://doi.org/10.1016/S1473-3099(13)70238-X  PMID: 24360892 
  48. van der Weerd W, Timmermans DR, Beaujean DJ, Oudhoff J, van Steenbergen JE. Monitoring the level of government trust, risk perception and intention of the general public to adopt protective measures during the influenza A (H1N1) pandemic in The Netherlands. BMC Public Health. 2011;11(1):575.  https://doi.org/10.1186/1471-2458-11-575  PMID: 21771296 
  49. Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber J, et al. VENICE project gatekeepers group. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Euro Surveill. 2014;19(16):20780.  https://doi.org/10.2807/1560-7917.ES2014.19.16.20780  PMID: 24786262 
  50. Kardas P, Zasowska A, Dec J, Stachurska M. Reasons for low influenza vaccination coverage: cross-sectional survey in Poland. Croat Med J. 2011;52(2):126-33.  https://doi.org/10.3325/cmj.2011.52.126  PMID: 21495194 
  51. Merchant RM, Elmer S, Lurie N. Integrating social media into emergency-preparedness efforts. N Engl J Med. 2011;365(4):289-91.  https://doi.org/10.1056/NEJMp1103591  PMID: 21793742 
  52. Lin L, Savoia E, Agboola F, Viswanath K. What have we learned about communication inequalities during the H1N1 pandemic: a systematic review of the literature. BMC Public Health. 2014;14(1):484.  https://doi.org/10.1186/1471-2458-14-484  PMID: 24884634 
  53. Nolan JM, Schultz PW, Cialdini RB, Goldstein NJ, Griskevicius V. Normative social influence is underdetected. Pers Soc Psychol Bull. 2008;34(7):913-23.  https://doi.org/10.1177/0146167208316691  PMID: 18550863 
  54. Schultz PW, Nolan JM, Cialdini RB, Goldstein NJ, Griskevicius V. The constructive, destructive, and reconstructive power of social norms. Psychol Sci. 2007;18(5):429-34.  https://doi.org/10.1111/j.1467-9280.2007.01917.x  PMID: 17576283 
  55. Brien S, Kwong JC, Buckeridge DL. The determinants of 2009 pandemic A/H1N1 influenza vaccination: a systematic review. Vaccine. 2012;30(7):1255-64.  https://doi.org/10.1016/j.vaccine.2011.12.089  PMID: 22214889 
  56. Nguyen T, Henningsen KH, Brehaut JC, Hoe E, Wilson K. Acceptance of a pandemic influenza vaccine: a systematic review of surveys of the general public. Infect Drug Resist. 2011;4:197-207. PMID: 22114512 
  57. World Health Organization (WHO). Evolution of a pandemic: A(H1N1) 2009, April 2009 - August 2010. Geneva: WHO; 2013. Available from: http://apps.who.int/iris/bitstream/10665/78414/1/9789241503051_eng.pdf?ua=1
  58. Mereckiene J, Cotter S, O’Flanagan D. National seasonal influenza vaccination survey for 2012–13 influenza season in EU/EEA (provisional data). Venice III Consortium; 2014. Available from: http://venice.cineca.org/VENICE_Seasonal_Influenza_2012-13_v10.pdf
Public preferences for vaccination programmes during pandemics caused by pathogens transmitted through respiratory droplets – a discrete choice experiment in four European countries, 2013
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Domino+Determann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Determann Domino</a>, <a href="/search?value1=Ida+J+Korfage&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Korfage Ida J</a>, <a href="/search?value1=Angela+Fagerlin&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fagerlin Angela</a>, <a href="/search?value1=Ewout+W+Steyerberg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Steyerberg Ewout W</a>, <a href="/search?value1=Michiel+C+Bliemer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bliemer Michiel C</a>, <a href="/search?value1=Helene+A+Voeten&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Voeten Helene A</a>, <a href="/search?value1=Jan+Hendrik+Richardus&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Richardus Jan Hendrik</a>, <a href="/search?value1=Mattijs+S+Lambooij&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lambooij Mattijs S</a>, <a href="/search?value1=Esther+W+de+Bekker-Grob&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Bekker-Grob Esther W</a></span>. Public preferences for vaccination programmes during pandemics caused by pathogens transmitted through respiratory droplets – a discrete choice experiment in four European countries, 2013. <a href="/content/ecdc">Euro Surveill.</a> 2016;21(22):pii=30247. <a href="https://doi.org/10.2807/1560-7917.ES.2016.21.22.30247" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2016.21.22.30247</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 18 Mar 2015;&nbsp;&nbsp; <span class="generated">Accepted</span>: 02 Jun 2016 </span> </p>
/content/10.2807/1560-7917.ES.2016.21.22.30247
/content/10.2807/1560-7917.ES.2016.21.22.30247
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error